ArticleBMC public health2025
Socioeconomic disparities in diabetes prevalence among the population in Ireland.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trends in Potentially Avoidable Hospitalisations Among People With Diabetes in Ireland; 2015-2024.Diabetes, obesity & metabolism · 2026Article
- Glycaemic benefits of smart insulin pens in socioeconomically deprived individuals: a single-Centre study.Irish journal of medical science · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionA large variation in diabetes prevalence by socioeconomic status (SES) persists internationally. This study aimed to quantify the prevalence of diabetes by age and SES and explore the current levels of inequality in the prevalence of diabetes in Ireland.
methodsAnnual cross-sectional self-reported diabetes data from the national population-based Healthy Ireland Survey for 2015-2023 (n = 59,933) were utilised. Highest educational attainment and area-based deprivation were used as SES indicators. Additionally, the differences in diabetes prevalence across population age-groups were reported. Socioeconomic differences and change in inequality over time were quantified using the relative index of inequality (RII). Logistic regression was used to estimate the relative risk (RR) for having self-reported diabetes according to age and SES, adjusted for sex and survey year.
resultsDiabetes prevalence was highest among individuals aged > 75 years (13.1%) compared to those aged < 40 years (1.0%). Similarly, prevalence was highest among the least educated (8.1%; RR = 2.73; 95% CI = 2.38, 3.13) compared to most educated (1.7%) and individuals living in most deprived areas (6.0%; RR = 2.18; 95% CI = 1.76, 2.70) compared to least deprived areas (2.2%). Additionally, the magnitude of relative inequalities as determined by education level were more than twofold greater than the magnitude of inequalities determined by area-based deprivation. Relative inequalities among individuals with diabetes persisted over the period 2015-2023 among the least educated (RII = 3.9; 95% CI = 3.3,4.6) and individuals living in the most deprived areas (RII = 3.65; 95% CI = 2.4,5.5). A slight increase in relative inequalities among the least educated, and a slight decline in relative inequalities among the most deprived was observed, however, these changes over time were not statistically significant.
conclusionThis is the first study to examine the socioeconomic variation of diabetes prevalence at the Irish population level. Significant differences in diabetes prevalence persist. With the ageing Irish population, this study highlights the need to consider potential effects of diabetes across the older populations and the lowest socioeconomic status groups when implementing equity-oriented diabetes prevention and management programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.